RxDoctor Payments Data

Charles Weber, MD

Glaucoma Specialist · Oregon City, ORNPI 1942447016

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Sight Sciences, Inc. at 55.8% of the total. 2025 is the largest year on record at $177, 2.6 times the $67 reported in 2019.

$453in general payments, 2019–2025

Across 14 payments — averaging $32.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$253
  • Alcon$127
  • Glaukos Corporation$37
  • Bausch & Lomb Americas Inc.$24
  • NEW World Medical,inc.$12
$5,491in research payments, 2019–2025

Across 19 payments — averaging $288.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Glaukos Corporation$5K

What the payments were for

  • Food & beverage$453100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few glaucoma specialist providers in Oregonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$262,289
Medicare patients
713
Services billed
2,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine41$36,433
LumiganBimatoprost54$19,982
Latanoprost1,372$16,046
Cyclosporine14$11,388
VyzultaLatanoprostene Bunod29$11,124
Prednisolone Acetate183$9,882
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat564$9,864
Travoprost64$8,698
Brinzolamide38$8,245
Brimonidine Tartrate418$7,458
RocklatanNetarsudil Mesylat/Latanoprost15$6,655
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol34$5,206
Timolol Maleate509$5,064
Timolol MaleateTimolol Maleate/Pf11$4,775
CombiganBrimonidine Tartrate/Timolol15$3,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Vyzulta$24$11,12429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Oregonon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Oregon City

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →